chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Covid after receiving the vaccine; Covid after receiving the vaccine; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 70-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 03Feb2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 02Mar2021 as dose 2, single (Lot number: EN6202), in left arm and on 18Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 70 years, in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The patient had not received any other vaccines within 4 weeks prior to the BNT162B2 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Covid after receiving the vaccine". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Post the vaccination, the patient has been tested for COVID-19. COVID after receiving the vaccine.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202200835354 similar report from same reporter;
Ever since getting vaccinated with the Pfizer shot I have become easily winded, headaches and have palpations.
migraine and chills; chills; Bruising and soreness at injection site; Bruising and soreness at injection site; This is a spontaneous case from a contactable consumer (patient). This 33-year-old female patient received dose 2 of BNT162B2 (PFIZER BIONTECH COVID-19 MRNA VACCINE; lot number EN5318) on 09Feb2021 (at the age of 33-years-old) as a single dose for COVID-19 immunization. Medical history included eczema, headaches, and benign tumor neck. Concomitant medications were none. Family history included Parkinon's disease and diabetes in the patient's father and diabetes, arthritis, kidney disease, psoriasis, fibromyalgia, glaucoma, and irritable bowel syndrome (IBS) in the patient's mother. The patient previously received dose 1 of BNT162B2 (lot number EL1283) on 19Jan2021 as a single dose in the right arm for COVID-19 immunization and experienced blistered burn and sensation of low grade current flowing through hands and sporadically throughout the limbs. On 10Feb2021, 25 hours after dose 2 of BNT162B2, the patient experienced migraine and chills. On an unspecified date after dose 2 of BNT162B2 the patient experienced bruising and soreness at injection site that lasted approximately 3 days. The patient was not hospitalized for the events. The patient did not receive any treatment for the events. The outcomes of migraine and chills were recovered after approximately 12 hours. The outcomes of bruising and soreness at injection site were recovered after approximately 3 days.   No follow-up attempts are needed. No further information expected.  Follow-Up (05APR2021): Follow-up attempts are completed. No further information is expected.
Information has been received from a company representative who was told by a Nurse Practitioner, that on 18Sep2012 a patient was given her second dose of GARDASIL (lot # 672547/1745AA, expiration date 13Sep2014), .5ml. The patient concomitantly received the FLUARIX (GSK manufacturer). It was reported that the patient's first dose of GARDASIL was administered 2 years prior. The following day (19Sep2012) the patient went to an emergency room because she was short of breath and had a fever of 102.4 degrees. It was unspecified if the fever and shortness of breath started on the 18Sep2012 or the following day. After waiting in the hospital for four hours, the patient left without receiving treatment. The following day the patient returned to her physician's office. Her temperature and breath were back to normal. The physician recommended that she drink fluids and take MOTRIN if needed. It was reported that the medication was not reintroduced. Additional information has been requested.
I was kind of feeling numbness like muscle ache in my arm; I have some muscle aches a lot in my arm; I was kind of feeling numbness like muscle ache in my arm; I have some muscle aches a lot in my arm; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 55-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Sep2022 as dose number unknown (booster), single (Batch/Lot number: unknown) at the age of 55 years for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (Primary Immunization series complete;  unknown manufacturer), for COVID-19 immunization. The following information was reported: MYALGIA (non-serious), HYPOAESTHESIA (non-serious) all with onset 09Sep2022, outcome "unknown" and all described as "I was kind of feeling numbness like muscle ache in my arm; I have some muscle aches a lot in my arm".  Additional information: Patient just had her shot this morning from Pharmacy and she was kind of feeling numbness like muscle ache in her arm and she was wondering like taking Tylenol for muscle ache would be okay.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Patient was dizzy and lightheaded, fainted but did not lose consciousness. Vitals normal.
pt recvd vax 5APR94 & 15APR was noted to have a fever of 102 & a rash over the site of innoculation & on face; MD saw the rash & felt it was consistent w/rubella rash;
Dizziness, Myalgia, Arthralgia, fever and chills Narrative:
The following 2 days after second dose with malaise, fatigue, myalgias, subjective fevers, third day post vaccine with chest pain consistent with myopericarditis after evaluation.  Echocardiogram pending, elevated ESR, CRP, Leukocytosis, elevated CPK level, Tropnins uptrending from 8, EKG with diffuse ST segment elevation and PR interval depression, clear CXR.
This spontaneous report was received from a Registered Nurse refers to a patient of unknown age and gender. No medical history, drug allergy, concurrent condition and concomitant medication was reported. On 25-FEB-2015, the patient was vaccinated with improperly stored M-M-R II (dose and lot number were not reported), subcutaneous. No adverse events were reported. No product quality complaint was involved. Additional information has been requested.
Ataxia, numbness lower extremities and hands, visual changes of both eyes (ex. increased time focusing).
First and second day of booster vaccine very tired, loss of energy and balance. On the third day, late afternoon became very confused. Eating dinner, was not able to complete thought process, not able to reach for correct item therefore grabbing salt/pepper shaker instead of water glass and tried to drink. Didn't have depth perception. Repeated conversation over and over again.
Information has been received from a nurse practitioner concerning a female child who was vaccinated with GARDASIL.  The patient had seizure after the vaccination.  The patient sought medical attention.  Upon internal review, seizure was determined to be an other important medical event.  This is one of several reports from the same source.  Additional information has been requested.
p/vax pt fainted outside of clinic; looked pale; felt dizzy; felt thirsty prior to fainting;
Fever; Fatigue; Body aches; This case was reported by a physician via call center representative and described the occurrence of fever in a 71-year-old patient who received Herpes zoster (Shingrix) (batch number XJ57B, expiry date 18th October 2021) for prophylaxis.   On 19th August 2019, the patient received Shingrix. On an unknown date, less than 2 months after receiving Shingrix, the patient experienced fever, fatigue and general body pain. On an unknown date, the outcome of the fever, fatigue and general body pain were unknown.   It was unknown if the reporter considered the fever, fatigue and general body pain to be related to Shingrix.  Additional case details were reported as follows: The patient experienced fever, fatigue, and body aches following a dose of Shingrix. No details related to start date or end dates of events was reported. The reporter consented to follow up.
No pain on injection to upper right deltiod, Pateint felt that it hit bone. Later patient described having "fever in arm". Pain and numbness that started later in the day and did not stop. Patient reported this event on 10/7/2013 and planning on asking PCP to check it.
Nose bleed; Feeling cold; Chills; Headache; Fatigue; This spontaneous case was reported by a pharmacist and describes the occurrence of EPISTAXIS (Nose bleed), CHILLS (Chills), HEADACHE (Headache), FATIGUE (Fatigue) and FEELING COLD (Feeling cold) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037KD3A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced EPISTAXIS (Nose bleed), CHILLS (Chills), HEADACHE (Headache), FATIGUE (Fatigue) and FEELING COLD (Feeling cold). At the time of the report, EPISTAXIS (Nose bleed) had not resolved and CHILLS (Chills), HEADACHE (Headache), FATIGUE (Fatigue) and FEELING COLD (Feeling cold) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication not reported. Treatment medication not provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the onset date of the reported events, a causal relationship cannot be excluded.
Pt recvd Hep B vax on 4MAR92 & 1APR92 & on 5APR92 pt devel a temp of 104, achiness, chills, h/a, severe fatigue & malaise; lab data for CBC, UA, chest x-ray, ECG & liver function tests were nl; pt hospitalized for 3 days & recovered;
Chief Complaint: low blood pressure, tachycardia, SOB after last Friday's Covid shot.  Pt. meeting SIRS criteria with elevated lactate, WBCs, and tachycardia.  Given fluid bolus and IV ABX.
She was patient at the COVID imz event today. She suddenly got very cold after her COVID  imz and her fingers turned blue. This happened while she was waiting the 15 minutes.   She did tell me she has Raynaud?s , however the room was very warm.  There was a nurse on site who evaluated her, checked BP, listened to lungs, HR. The nurse stayed with her and I checked on her periodically.  After about 30 minutes she felt fine and returned to work.  She did tell me she was a little skittish about getting shots  when I gave her the vaccine.
Site of injection had normal pain and swelling at first; Site of injection had normal pain and swelling at first; Itchy; Booster; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).   A 58 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 04Dec2021 07:30 (Batch/Lot number: unknown) at the age of 58 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included Allergy to shellfish (unspecified if ongoing); Allergy to Grapes (unspecified if ongoing); Allergy to penicillin (unspecified if ongoing); Allergy to Iodine (unspecified if ongoing). The patient took concomitant medications. Vaccination history included Bnt162b2 (Dose Number: 2, Batch/Lot No: Unknown. Unable to locate or read the details, Location of injection: Arm Right, Vaccine Administration Time: 01:30 PM), administration date: 07May2021, when the patient was 58 years old, for COVID-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: Unknown. Unable to locate or read the details, Location of injection: Arm Right, Vaccine Administration Time: 01:30 PM), administration date: 17Apr2021, when the patient was 57 years old, for COVID-19 immunization. The following information was reported IMMUNISATION (non-serious) with onset 04Dec2021 07:00, outcome unknown; VACCINATION SITE SWELLING (non-serious), VACCINATION SITE PAIN (non-serious) all with onset 04Dec2021 23:30, outcome recovering; PRURITUS (non-serious) with onset 04Dec2021 23:30, outcome not recovered. Therapeutic measures were not taken as a result of vaccination site swelling, vaccination site pain, pruritus. Additional info-It was reported that patient did not receive any other vaccine in four weeks. Patient did not suffer from covid prior vaccination and did not underwent covid tested post vaccination. It was also reported that patient medical history list was too long. Patient had experienced Site of injection had normal pain and swelling at first. Over the next days, the swollen, hard area spread to the size of my palm and became itchy. Now it has stopped growing larger, but is still itchy (4 days later). The lot number for bnt162b2 was not provided and will be requested during follow up.
The booster of the Pfizer covid booster shot; The booster of the Pfizer covid booster shot; Had such pain from all her arthritic joints; Pounding headache; Right arm is still swollen but not terrible; This is a spontaneous report received from a contactable consumer (patient). An 85-year-old female patient received third dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Batch/Lot Number: 301308A), via an unspecified route of administration, administrated in right arm on 16Sep2021 11:30 (age at the time of vaccination 85-years-old), as a 0.3ml single dose for COVID-19 immunization. The patient's medical history included Arthritis, at arthritis clinic diagnosed the caller has had this since she was in her 70s. The patient's concomitant medications included Chondroitin once a day, Glucosamine once a day, and Omega 3. Patient previously received first dose of BNT162B2 vaccine (Batch/Lot Number: EN5318), via an unspecified route of administration on 15Feb2021 (age at the time of vaccination 84-years-old), as a single dose for COVID-19 immunization, and second dose of BNT162B2 vaccine, via an unspecified route of administration on 26Feb2021 (age at the time of vaccination 84-years-old), as a single dose for COVID-19 immunization. On 16Sep2021, the patient experienced the booster of the Pfizer covid booster shot, had such pain from all her arthritic joints, pounding headache; and on an unspecified date Sep2021 right arm is still swollen but not terrible. The caller took Chondroitin, glucosamine and two Tylenols and is feeling a little better. Patient did not visit to emergency room or physician office. No Prior Vaccinations within 4 weeks. The outcome of the event the booster of the Pfizer covid booster shot was unknown; and right arm is still swollen but not terrible was recovered on an unspecified date Sep2021; and other events was not recovered.  Follow-Up (22Sep2021): Follow-up attempts are completed. No further information is expected.
no taste; no smell; headache; nausea; chills; Body aches; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Body aches), AGEUSIA (no taste), ANOSMIA (no smell), HEADACHE (headache) and NAUSEA (nausea) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M201A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Hypertension, Cholesterol, Lung disorder and Heart disorder.    On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, the patient experienced PAIN (Body aches), HEADACHE (headache), NAUSEA (nausea) and CHILLS (chills). On 16-Feb-2021, the patient experienced AGEUSIA (no taste) and ANOSMIA (no smell). At the time of the report, PAIN (Body aches), HEADACHE (headache), NAUSEA (nausea) and CHILLS (chills) had resolved and AGEUSIA (no taste) and ANOSMIA (no smell) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications included blood pressure, heart, cholesterol and lungs medication. Treatment details were not reported by the reporter.
Vaccine administered at clinic visit 4/3/14. Client also prescribed Metronidazole and reports starting antibiotic same day. C/O rash, itchiness, left leg pain, confusion, dizziness. Rash/itchiness subsided. Client still reports "not feeling well".
A report was received from a health care professional on 7OCT2003, concerning a female vaccinee who inadvertantly received Fluvirin vaccine SC on 6OCT2003. On 6OCT2003, an obese female vaccinee inadvertantly received a 0.51 Fluvirin dose SC instead of IMwith the use of a 5/8 inch needle. No adverse signs or symptoms were noted at the time of the report. There was insufficient information to determine the reporter's causality assessment. Further information was received from a health care professional on 2JAN2004 indicating that no adverse outcome was reported. No follow up pending as no further information is available.
experienced headache after second COVID-19 vaccine; This is a spontaneous report from a non-contactable physician.  A male patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, batch/lot number and expiration date were not reported), via an unspecified route on unspecified date as single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced headache after second COVID-19 vaccine on an unspecified date. The outcome of the event was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient was vaccinated but was out of out of recommended age range.  Pharmacist did not recognize error until after injection was complete.  Patient did not have any post-injection reaction.
Immediate sever pain in left shoulder/armpit region after receiving flu shot. (injection was given very high on my arm, about 1 inch toward my back from the top of my shoulder). Painful range of motion in shoulder. As of 11/13/14, pain has not subsided, there is still painful range of motion. Went to doctor on 11/12/14, and he prescribed a steroid and physical therapy type exercises/stretches to perform daily until healed. Instructed to not exercise using my left shoulder until healed.
This is a spontaneous report from a non-contactable consumer reporting for herself. This 64-year-old consumer got pneumonia before and was hospitalized and received PVD23 afterwards which brought her back to normal. She reported that after five years she got pneumonia again and now she went up to the pharmacy and the guy didn't look up and gave her PREVNAR13 and she had bad side effects as it included bacterial stuff. The consumer also mentioned that she could not have that stuff as she had horrible reaction after seven nights she got the shot and got sick after the very bad reaction. The consumer mentioned that PREVNAR13 was bacterial toxin stuff and she had ringing in her ears. The consumer mentioned the name of the product as PVC13 from PREVNAR. No follow-up attempts possible. No further information expected.
Pharmacist failed to dilute the Pfizer covid-19 vaccine vial so patient received almost 6x the recommended dose.  Spoke with patient 3 days later and he said he was tired the next day but felt fine otherwise
hair loss; This spontaneous case was reported by a consumer and describes the occurrence of ALOPECIA (hair loss) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Mar-2021, the patient experienced ALOPECIA (hair loss). At the time of the report, ALOPECIA (hair loss) outcome was unknown. Not Provided          No concomitant medication were reported. No treatment medication details were reported. The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the mRNA-1273 in response to the events was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 07-May-2021: Follow-up received on 07-MAY-2021. additional information: patient demographics
Lightheaded and dizzy 15 minutes after injection. Slightly queasy and dizzy for over 24 hours and then it seemed like I was getting better. Went to bed and woke up 38 hours after injection and had extreme vertigo. Couldn't walk straight and had a strong pulling to the right. Going to drink lots of water and sit or lay down today hoping it passes. I am 66 years old, 5'11" and weigh 155 pounds. I ride a bike 40 miles per week and am in good to excellent health.
L arm where both menveo and gardasil were injected became swollen and pink and warm to the touch all the way from the deltoid injection site down to the elbow. Patient was otherwise ok and he was not in any pain.
Patient received flu vaccine on 10/21/2005, about 3 hours later, experienced raised, red bumps on left side of her face with pain and itching and complaint of headache.  Went to local ER and then to MD.  Diagnosed as shingles.
expired vaccine used; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (expired vaccine used) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049E21A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (expired vaccine used). On 12-Nov-2021, EXPIRED PRODUCT ADMINISTERED (expired vaccine used) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided. No treatment medication were provided   Most recent FOLLOW-UP information incorporated above includes: On 19-Nov-2021: Follow Up received contains no significant information.; Sender's Comments: Case is non-serious no CC needed
R shoulder area painful, red, hot, indurated about 24 hours after vaccine. It is from acromion process to mid humerus (about 5 inches vertical) and 6 inches from mid-anterior arm to mid-posterior arm.
Left arm has "never been the same" since vaccination, weakness and painful when raising. Bleeding from injection site at time of vaccination and 2" diameter bruise. Has not shared this info with primary care Dr. yet.
Mother called to say that the child had a fever approximately 24 hours post vax to 101. Given Tylenol every 6 hours and had decreased.
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age (gender not reported). On 05-NOV-2013 the patient was vaccinated with a dose of GARDASIL (lot # J008423, exp. date 21-JAN-2016) (route and dose not reported) which was exposed to a low temperature of 29F for a total of 11 hours from 30-OCT-2013 until 07-NOV-2013. These excursions were not supported. No adverse effects were reported. This is one of several reports from same source. Additional information has been requested.